| Year |
Citation |
Score |
| 2020 |
Gillis A, Kliewer A, Kelly E, Henderson G, Christie MJ, Schulz S, Canals M. Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor. Trends in Pharmacological Sciences. PMID 33097283 DOI: 10.1016/j.tips.2020.09.009 |
0.44 |
|
| 2020 |
Gillis A, Gondin AB, Kliewer A, Sanchez J, Lim HD, Alamein C, Manandhar P, Santiago M, Fritzwanker S, Schmidel F, Katte TA, Reekie T, Grimsey NL, Kassiou M, Kellam B, ... ... Schulz S, et al. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Science Signaling. 13. PMID 32234959 DOI: 10.1126/scisignal.aaz3140 |
0.44 |
|
| 2018 |
Miess E, Gondin AB, Yousuf A, Steinborn R, Mösslein N, Yang Y, Göldner M, Ruland JG, Bünemann M, Krasel C, Christie MJ, Halls ML, Schulz S, Canals M. Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization. Science Signaling. 11. PMID 30018083 DOI: 10.1126/scisignal.aas9609 |
0.44 |
|
| 2017 |
Günther T, Dasgupta P, Mann A, Miess E, Kliewer A, Fritzwanker S, Steinborn R, Schulz S. Targeting multiple opioid receptors - improved analgesics with reduced side effects? British Journal of Pharmacology. PMID 28378462 DOI: 10.1111/bph.13809 |
0.44 |
|
| 2016 |
Günther T, Culler M, Schulz S. Research Resource: Real-time analysis of somatostatin and dopamine receptor signaling in pituitary cells using a fluorescence-based membrane potential assay. Molecular Endocrinology (Baltimore, Md.). me20151241. PMID 26967369 DOI: 10.1210/me.2015-1241 |
0.6 |
|
| 2015 |
Moulédous L, Froment C, Burlet-Schiltz O, Schulz S, Mollereau C. Phosphoproteomic analysis of the mouse brain mu-opioid (MOP) receptor. Febs Letters. 589: 2401-8. PMID 26226422 DOI: 10.1016/j.febslet.2015.07.025 |
0.6 |
|
| 2015 |
Yousuf A, Miess E, Sianati S, Du YP, Schulz S, Christie M. The Role of Phosphorylation Sites in Desensitization of μ-Opioid Receptor. Molecular Pharmacology. PMID 25969388 DOI: 10.1124/mol.115.098244 |
0.6 |
|
| 2015 |
Kaemmerer D, Wirtz RM, Fischer EK, Hommann M, Sänger J, Prasad V, Specht E, Baum RP, Schulz S, Lupp A. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm. Pancreas. 44: 648-54. PMID 25872131 DOI: 10.1097/MPA.0000000000000316 |
0.6 |
|
| 2015 |
Bowman SL, Soohoo AL, Shiwarski DJ, Schulz S, Pradhan AA, Puthenveedu MA. Cell-autonomous regulation of Mu-opioid receptor recycling by substance P. Cell Reports. 10: 1925-36. PMID 25801029 DOI: 10.1016/j.celrep.2015.02.045 |
0.6 |
|
| 2015 |
Lupp A, Mann A, Heeb A, Kaemmerer D, Sänger J, Evert M, Evert K, Mawrin C, Schulz S. Reassessment of endothelin receptor A expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-8. Peptides. 66: 19-25. PMID 25708416 DOI: 10.1016/j.peptides.2015.02.005 |
0.6 |
|
| 2015 |
Ádori C, Glück L, Barde S, Yoshitake T, Kovacs GG, Mulder J, Maglóczky Z, Havas L, Bölcskei K, Mitsios N, Uhlén M, Szolcsányi J, Kehr J, Rönnbäck A, Schwartz T, ... ... Schulz S, et al. Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: new aspects on Alzheimer's disease. Acta Neuropathologica. 129: 541-63. PMID 25676386 DOI: 10.1007/s00401-015-1394-3 |
0.6 |
|
| 2015 |
Specht E, Kaemmerer D, Sänger J, Wirtz RM, Schulz S, Lupp A. Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms. Histopathology. PMID 25641082 DOI: 10.1111/his.12662 |
0.6 |
|
| 2015 |
Lee M, Lupp A, Mendoza N, Martin N, Beschorner R, Honegger J, Schlegel J, Shively T, Pulz E, Schulz S, Roncaroli F, Pellegata NS. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocrine-Related Cancer. 22: 111-9. PMID 25515731 DOI: 10.1530/ERC-14-0472 |
0.6 |
|
| 2015 |
Kaemmerer D, Specht E, Sänger J, Wirtz RM, Sayeg M, Schulz S, Lupp A. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers. The Journal of Clinical Endocrinology and Metabolism. 100: 831-40. PMID 25494861 DOI: 10.1210/jc.2014-2699 |
0.6 |
|
| 2014 |
Ebbinghaus M, Gajda M, Holtzman MJ, Schulz S, Schaible HG. Does chloride channel accessory 3 have a role in arthritis pain? A study on murine antigen-induced arthritis. Neuroscience Letters. 576: 40-4. PMID 24905173 DOI: 10.1016/j.neulet.2014.05.051 |
0.6 |
|
| 2014 |
Madishetti S, Schneble N, König C, Hirsch E, Schulz S, Müller JP, Wetzker R. PI3Kγ integrates cAMP and Akt signalling of the μ-opioid receptor. British Journal of Pharmacology. 171: 3328-37. PMID 24654606 DOI: 10.1111/bph.12698 |
0.6 |
|
| 2014 |
Lehmann A, Kliewer A, Märtens JC, Nagel F, Schulz S. Carboxyl-terminal receptor domains control the differential dephosphorylation of somatostatin receptors by protein phosphatase 1 isoforms. Plos One. 9: e91526. PMID 24637622 DOI: 10.1371/journal.pone.0091526 |
0.6 |
|
| 2014 |
Glück L, Loktev A, Moulédous L, Mollereau C, Law PY, Schulz S. Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5. Biological Psychiatry. 76: 767-74. PMID 24629717 DOI: 10.1016/j.biopsych.2014.01.021 |
0.6 |
|
| 2014 |
Lehmann A, Kliewer A, Schütz D, Nagel F, Stumm R, Schulz S. Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor. Molecular and Cellular Endocrinology. 387: 44-51. PMID 24565897 DOI: 10.1016/j.mce.2014.02.009 |
0.6 |
|
| 2014 |
Schulz S, Lehmann A, Kliewer A, Nagel F. Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5. British Journal of Pharmacology. 171: 1591-9. PMID 24328848 DOI: 10.1111/bph.12551 |
0.6 |
|
| 2013 |
Lambertini C, Barzaghi-Rinaudo P, D'Amato L, Schulz S, Nuciforo P, Schmid HA. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. Regulatory Peptides. 187: 35-41. PMID 24188818 DOI: 10.1016/j.regpep.2013.10.007 |
0.6 |
|
| 2013 |
Mueller W, Schütz D, Nagel F, Schulz S, Stumm R. Hierarchical organization of multi-site phosphorylation at the CXCR4 C terminus. Plos One. 8: e64975. PMID 23734232 DOI: 10.1371/journal.pone.0064975 |
0.6 |
|
| 2013 |
Remke M, Hering E, Gerber NU, Kool M, Sturm D, Rickert CH, Gerß J, Schulz S, Hielscher T, Hasselblatt M, Jeibmann A, Hans V, Ramaswamy V, Taylor MD, Pietsch T, et al. Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma. Child's Nervous System : Chns : Official Journal of the International Society For Pediatric Neurosurgery. 29: 1253-62. PMID 23677175 DOI: 10.1007/s00381-013-2142-4 |
0.6 |
|
| 2013 |
Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacological Reviews. 65: 223-54. PMID 23321159 DOI: 10.1124/pr.112.005942 |
0.6 |
|
| 2010 |
Jacobs S, Calebiro D, Nikolaev VO, Lohse MJ, Schulz S. Real-time monitoring of somatostatin receptor-cAMP signaling in live pituitary. Endocrinology. 151: 4560-5. PMID 20610560 DOI: 10.1210/en.2010-0341 |
0.6 |
|
| 2010 |
Klenk C, Schulz S, Calebiro D, Lohse MJ. Agonist-regulated cleavage of the extracellular domain of parathyroid hormone receptor type 1. The Journal of Biological Chemistry. 285: 8665-74. PMID 20080964 DOI: 10.1074/jbc.M109.058685 |
0.6 |
|
| 2009 |
Schmitt JP, Ahmad F, Lorenz K, Hein L, Schulz S, Asahi M, Maclennan DH, Seidman CE, Seidman JG, Lohse MJ. Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition. Circulation. 119: 436-44. PMID 19139388 DOI: 10.1161/CIRCULATIONAHA.108.783506 |
0.6 |
|
| Show low-probability matches. |